Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Change in Accured Expenses (2021 - 2025)

Historic Change in Accured Expenses for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $11.0 million.

  • ARS Pharmaceuticals' Change in Accured Expenses rose 15268.5% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.6 million, marking a year-over-year increase of 2709090.91%. This contributed to the annual value of $16.4 million for FY2024, which is 69171.77% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Change in Accured Expenses of $11.0 million as of Q3 2025, which was up 15268.5% from $12.8 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Change in Accured Expenses registered a high of $12.8 million during Q2 2025, and its lowest value of -$11.4 million during Q4 2022.
  • Moreover, its 5-year median value for Change in Accured Expenses was $1.3 million (2024), whereas its average is $1.7 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first plummeted by 10967.33% in 2022, then soared by 126875.0% in 2024.
  • ARS Pharmaceuticals' Change in Accured Expenses (Quarter) stood at -$5.4 million in 2021, then crashed by 109.67% to -$11.4 million in 2022, then grew by 22.25% to -$8.9 million in 2023, then surged by 186.51% to $7.7 million in 2024, then skyrocketed by 42.7% to $11.0 million in 2025.
  • Its Change in Accured Expenses stands at $11.0 million for Q3 2025, versus $12.8 million for Q2 2025 and $4.2 million for Q1 2025.